SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on August 12, 2014. The report addresses operational highlights for the quarter ended June 30, 2014, and outlines anticipated corporate and clinical milestones for the remainder of 2014 and 2015. The filing incorporates a press release dated August 12, 2014, as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a press release containing operational highlights rather than a detailed financial statement.
Material Changes
The filing does not contain specific comparative financial data to quantify material changes versus the prior period. It references the announcement of operational highlights and future milestones but does not detail the magnitude of changes in the text provided.
Guidance, Outlook, and Risks
Management provided anticipated corporate and clinical milestones for the remainder of 2014 and 2015 in the referenced press release. The filing explicitly states that the information under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific operational highlights and milestone details.
- Verify the company's current name, as the metadata references "Dare Bioscience, Inc." while the filing is for "Cerulean Pharma Inc."
- Consult the company's most recent 10-Q or 10-K for detailed financial metrics (revenue, cash flow, debt) not included in this 8-K.
- Confirm the status of clinical trials and corporate milestones for 2014 and 2015 against the latest regulatory filings.